<DOC>
	<DOCNO>NCT00520468</DOCNO>
	<brief_summary>Objectives : Primary : To evaluate response rate total cytokine-immunotherapy low-risk myelodysplastic syndrome ( MDS ) . Secondary : To evaluate response duration , survival side effect treatment .</brief_summary>
	<brief_title>Treatment Myelodysplastic Syndrome ( MDS ) With Cytokine-Immunotherapy Low-Risk MDS</brief_title>
	<detailed_description>MDS disease produce low blood count may cause anemia , infection , and/or bleeding . Erythropoietin Granulocyte colony-stimulating factor ( G-CSF GCSF ) drug stimulate production red cell white cell . Prednisone cyclosporin drug work MDS affect immune system . Before start treatment study , call `` screening test '' . These test help doctor decide eligible take part study . You complete medical history physical exam . Routine blood test ( 4-6 tablespoon ) perform . You bone marrow aspiration . To collect bone marrow aspirate , area hip chest bone numb anesthetic small amount bone marrow withdrawn large needle . Women able child must negative blood urine pregnancy test . If find eligible take part study , receive erythropoietin injection skin week G-CSF injection skin 1-2 time week long respond well treatment . You take prednisone mouth every day month cyclosporin tablet mouth every day 6 month . During study , need visit doctor physical exam measurement vital sign . The frequency doctor visit vary depend physical condition , require least every 3 month . Blood test ( 2 teaspoon ) do every 1-2 week first 12 week treatment , every 2 4 week remainder study . The blood sample collect routine lab test . Periodic ( every 3 6 month ) bone marrow sample also take check cell related disease , , completion study . You take study disease get bad intolerable side effect occur . This investigational study . All drug FDA approve commercially available . Up 60 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Patients MDS &lt; /= 10 % blast International Prognostic Scoring System ( IPSS ) low intermediate 1 . No prior intensive chemotherapy highdose araC ( &gt; /= 1g/m2 ) . Prior cytokine , biologic therapy , targeted therapy , single agent chemotherapy allow . Procrit , GCSF allow therapy . Patients blast &lt; 5 % must indication therapy , transfusion need , symptomatic anemia Hb &lt; 11g/dl , platelet &lt; 100 x 10 9/L , granulocyte &lt; 10 9/L . 2 . Performance 02 ( Eastern Cooperative Oncology Group ( ECOG ) ) . Adequate liver function ( bilirubin &lt; 2mg/dl ) renal function ( creatinine &lt; 2mg/dl ) . Adequate cardiac function ( New York Heart Association ( NYHA ) cardiac IIIIV exclude ) 3 . Signed informed consent 1 . Nursing pregnant female exclude . Women childbearing potential practice effective method contraception . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 2 . Patients active uncontrolled infection .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Darbepoetin alfa</keyword>
	<keyword>Aranesp</keyword>
	<keyword>Erythropoiesis stimulate protein</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Cyclosporin A</keyword>
	<keyword>Sandimmune</keyword>
	<keyword>CYA</keyword>
	<keyword>Cyclosporine</keyword>
</DOC>